Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $81.71 -3.77%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
RIBT, INLB, FTXP, More
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
RIBT, INLB, FTXP, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.20), $0.09 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $23.53 million versus the consensus estimate of $21.74 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Piper Sandler: 'Amazon.com (AMZN) AMZN Looks Best Positioned'
- KeyBanc on National Fuel Gas (NFG): 'P&S Growth an Underappreciated Hedge to Weak Natural Gas Prices'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
